{"schema_version":"secwatch.filing_event.v1","accession":"0001567892-24-000015","form_type":"8-K","ticker":null,"cik":"0001567892","company_name":"Keenova Therapeutics plc","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.004789+00:00","generated_at":"2026-06-02T05:55:20.376552+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mallinckrodt Q1 net sales up 10.2% to $467.8M; net loss improves 73.8%","bullets":["Net sales of $467.8M, up 10.2% YoY on a reported and constant currency basis.","Net loss of $65.4M, a 73.8% improvement from $249.3M in prior year quarter.","Adjusted EBITDA $144.9M, up 17.3% YoY from $123.5M.","Acthar Gel net sales $102.8M (+25.4%), Terlivaz $6.0M; Specialty Generics +22.0%.","Full year guidance reaffirmed; SelfJect launch expected in Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001567892-24-000015","json":"https://secwatch.observer/filing/0001567892-24-000015.json","markdown":"https://secwatch.observer/filing/0001567892-24-000015.md","text":"https://secwatch.observer/filing/0001567892-24-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567892/000156789224000015/0001567892-24-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567892/000156789224000015/mnk-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:55:20.376552+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04a64cb730c983a6ac4af63703f2818536229a8e","claim":"Keenova Therapeutics plc reported the first quarter ended March 29, 2024 results: revenue $467.8 million, net income net loss of $65.4 million. Guidance reaffirmed.","evidence_excerpt":"in such a filing. --- EX-99.1 (EX-99.1) --- Mallinckrodt plc Reports First Quarter 2024 Financial Results and Reaffirms Full Year Guidance Achieves First Quarter Net Sales of $467.8 Million, Reflecting 10.2% Year-Over-Year Growth on a Reported and Constant Currency Basis Reports Net Loss of $65.4 Million , Reflecting a 73.8% Year-Over-Year Improvement; Delivers","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000156789224000015/0001567892-24-000015-index.htm","confidence":0.88,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 29, 2024"},{"label":"Revenue","value":"$467.8 million"},{"label":"Net income","value":"net loss of $65.4 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}